-+ 0.00%
-+ 0.00%
-+ 0.00%

The FDA Has Granted Fast Track Designation To PureTech Health's LYT-200 For Acute Myeloid Leukemia

Benzinga·01/09/2025 12:08:24
Listen to the news
  • Single agent and combination data from Phase 1b AML/MDS trial presented at ASH 2024 showed potential of LYT-200 to serve broad range of patients across various lines of treatment
  • LYT-200 is currently being evaluated in two Phase 1/2 trials for the potential treatment of AML/MDS and head and neck cancers